Cargando…

Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins

Alzheimer’s disease (AD) is the most common form of dementia that usually occurs among older people. AD results from neuronal degeneration that leads to the cognitive impairment and death. AD is incurable, typically develops over the course of many years and is accompanied by a loss of functional au...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulichikhin, Konstantin Y., Fedotov, Sergei A., Rubel, Maria S., Zalutskaya, Natalia M., Zobnina, Anastasia E., Malikova, Oksana A., Neznanov, Nikolay G., Chernoff, Yury O., Rubel, Aleksandr A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096329/
https://www.ncbi.nlm.nih.gov/pubmed/33910450
http://dx.doi.org/10.1080/19336896.2021.1917289
_version_ 1783688138840866816
author Kulichikhin, Konstantin Y.
Fedotov, Sergei A.
Rubel, Maria S.
Zalutskaya, Natalia M.
Zobnina, Anastasia E.
Malikova, Oksana A.
Neznanov, Nikolay G.
Chernoff, Yury O.
Rubel, Aleksandr A.
author_facet Kulichikhin, Konstantin Y.
Fedotov, Sergei A.
Rubel, Maria S.
Zalutskaya, Natalia M.
Zobnina, Anastasia E.
Malikova, Oksana A.
Neznanov, Nikolay G.
Chernoff, Yury O.
Rubel, Aleksandr A.
author_sort Kulichikhin, Konstantin Y.
collection PubMed
description Alzheimer’s disease (AD) is the most common form of dementia that usually occurs among older people. AD results from neuronal degeneration that leads to the cognitive impairment and death. AD is incurable, typically develops over the course of many years and is accompanied by a loss of functional autonomy, making a patient completely dependent on family members and/or healthcare workers. Critical features of AD are pathological polymerization of Aβ peptide and microtubule-associated protein tau, accompanied by alterations of their conformations and resulting in accumulation of cross-β fibrils (amyloids) in human brains. AD apparently progresses asymptomatically for years or even decades before the appearance of symptoms. Therefore, development of the early AD diagnosis at a pre-symptomatic stage is essential for potential therapies. This review is focused on current and potential molecular tools (including non-invasive methods) that are based on detection of amyloidogenic proteins and can be applicable to early diagnosis of AD. Abbreviations: Aβ – amyloid-β peptide; AβO – amyloid-β oligomers; AD – Alzheimer’s disease; ADRDA – Alzheimer’s Disease and Related Disorders Association; APH1 - anterior pharynx defective 1; APP – amyloid precursor protein; BACE1 – β-site APP-cleaving enzyme 1; BBB – brain blood barrier; CJD - Creutzfeldt-Jakob disease; CRM – certified reference material; CSF – cerebrospinal fluid; ELISA – enzyme-linked immunosorbent assay; FGD – (18)F-fluorodesoxyglucose (2-deoxy-2-[(18)F]fluoro-D-glucose); IP-MS – immunoprecipitation-mass spectrometry assay; MCI – mild cognitive impairment; MDS – multimer detection system; MRI – magnetic resonance imaging; NIA-AA – National Institute on Ageing and Alzheimer’s Association; NINCDS – National Institute of Neurological and Communicative Disorders and Stroke; PEN2 – presenilin enhancer 2; PET – positron emission tomography; PiB – Pittsburgh Compound B; PiB-SUVR - PIB standardized uptake value ratio; PMCA – Protein Misfolding Cycling Amplification; PrP – Prion Protein; P-tau – hyperphosphorylated tau protein; RMP – reference measurement procedure; RT-QuIC - real-time quaking-induced conversion; SiMoA – single-molecule array; ThT – thioflavin T; TSEs – Transmissible Spongiform Encephslopathies; T-tau – total tau protein
format Online
Article
Text
id pubmed-8096329
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-80963292021-05-13 Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins Kulichikhin, Konstantin Y. Fedotov, Sergei A. Rubel, Maria S. Zalutskaya, Natalia M. Zobnina, Anastasia E. Malikova, Oksana A. Neznanov, Nikolay G. Chernoff, Yury O. Rubel, Aleksandr A. Prion Review Alzheimer’s disease (AD) is the most common form of dementia that usually occurs among older people. AD results from neuronal degeneration that leads to the cognitive impairment and death. AD is incurable, typically develops over the course of many years and is accompanied by a loss of functional autonomy, making a patient completely dependent on family members and/or healthcare workers. Critical features of AD are pathological polymerization of Aβ peptide and microtubule-associated protein tau, accompanied by alterations of their conformations and resulting in accumulation of cross-β fibrils (amyloids) in human brains. AD apparently progresses asymptomatically for years or even decades before the appearance of symptoms. Therefore, development of the early AD diagnosis at a pre-symptomatic stage is essential for potential therapies. This review is focused on current and potential molecular tools (including non-invasive methods) that are based on detection of amyloidogenic proteins and can be applicable to early diagnosis of AD. Abbreviations: Aβ – amyloid-β peptide; AβO – amyloid-β oligomers; AD – Alzheimer’s disease; ADRDA – Alzheimer’s Disease and Related Disorders Association; APH1 - anterior pharynx defective 1; APP – amyloid precursor protein; BACE1 – β-site APP-cleaving enzyme 1; BBB – brain blood barrier; CJD - Creutzfeldt-Jakob disease; CRM – certified reference material; CSF – cerebrospinal fluid; ELISA – enzyme-linked immunosorbent assay; FGD – (18)F-fluorodesoxyglucose (2-deoxy-2-[(18)F]fluoro-D-glucose); IP-MS – immunoprecipitation-mass spectrometry assay; MCI – mild cognitive impairment; MDS – multimer detection system; MRI – magnetic resonance imaging; NIA-AA – National Institute on Ageing and Alzheimer’s Association; NINCDS – National Institute of Neurological and Communicative Disorders and Stroke; PEN2 – presenilin enhancer 2; PET – positron emission tomography; PiB – Pittsburgh Compound B; PiB-SUVR - PIB standardized uptake value ratio; PMCA – Protein Misfolding Cycling Amplification; PrP – Prion Protein; P-tau – hyperphosphorylated tau protein; RMP – reference measurement procedure; RT-QuIC - real-time quaking-induced conversion; SiMoA – single-molecule array; ThT – thioflavin T; TSEs – Transmissible Spongiform Encephslopathies; T-tau – total tau protein Taylor & Francis 2021-04-29 /pmc/articles/PMC8096329/ /pubmed/33910450 http://dx.doi.org/10.1080/19336896.2021.1917289 Text en © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Kulichikhin, Konstantin Y.
Fedotov, Sergei A.
Rubel, Maria S.
Zalutskaya, Natalia M.
Zobnina, Anastasia E.
Malikova, Oksana A.
Neznanov, Nikolay G.
Chernoff, Yury O.
Rubel, Aleksandr A.
Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins
title Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins
title_full Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins
title_fullStr Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins
title_full_unstemmed Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins
title_short Development of molecular tools for diagnosis of Alzheimer’s disease that are based on detection of amyloidogenic proteins
title_sort development of molecular tools for diagnosis of alzheimer’s disease that are based on detection of amyloidogenic proteins
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096329/
https://www.ncbi.nlm.nih.gov/pubmed/33910450
http://dx.doi.org/10.1080/19336896.2021.1917289
work_keys_str_mv AT kulichikhinkonstantiny developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins
AT fedotovsergeia developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins
AT rubelmarias developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins
AT zalutskayanataliam developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins
AT zobninaanastasiae developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins
AT malikovaoksanaa developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins
AT neznanovnikolayg developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins
AT chernoffyuryo developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins
AT rubelaleksandra developmentofmoleculartoolsfordiagnosisofalzheimersdiseasethatarebasedondetectionofamyloidogenicproteins